Focal Tumors: Extraprostatic
Characteristics of tumors that extend beyond the prostate but are still treatable by focal modalities are demonstrated with 3D ultrasound, Doppler imaging, MRI, DWI-MRI, and DCE-MRI.
- PDF / 26,221,963 Bytes
- 269 Pages / 504.63 x 737.01 pts Page_size
- 31 Downloads / 176 Views
123
Image Guided Prostate Cancer Treatments
Robert L. Bard • Jurgen J. Fütterer Dan Sperling Editors
Image Guided Prostate Cancer Treatments
Editors Robert L. Bard, MD Bard Cancer Center Biofoundation for Angiogenesis Research and Development New York, NY USA
Dan Sperling, MD Sperling Prostate Center, Alpha 3T MRI New York, NY USA
Jurgen J. Fütterer, MD, PhD Department of Radiology Radboud University Nijmegen Medical Centre HB Nijmegen The Netherlands
ISBN 978-3-642-40428-3 ISBN 978-3-642-40429-0 DOI 10.1007/978-3-642-40429-0 Springer Heidelberg New York Dordrecht London
(eBook)
© Springer-Verlag Berlin Heidelberg 2014 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher's location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. While the advice and information in this book are believed to be true and accurate at the date of publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein. Printed on acid-free paper Springer is part of Springer Science+Business Media (www.springer.com)
To my patients, whose courage showed me possibility To my wife, Loreto, whose vision generated reality
Foreword
With an estimated 238,590 new cases in 2013, prostate cancer is the most common cancer in men in the USA. One in 6 men will be diagnosed with this disease in his lifetime. It is, at the same time, the second biggest killer in men, with an estimated 29,720 deaths in 2013 in the USA. As for other cancers in the past, the science of prostate cancer has changed tremendously during the last 10 years. Premalignant conditions have been described leading to an extremely active search fo
